Bain buys 50 per cent stake in pharmaceutical venture from DSM

05 July 2018
Pharma

Bain Capital Private Equity has agreed to acquire DSM Sinochem Pharmaceuticals (DSP), the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP is a 50/50 joint venture of Heerlen-based DSM and Sinochem of Beijing. DSM said it was paid about €250m for its stake in the group. In 2017, DSP generated sales of approximately €440m. It has manufacturing sites and sales offices in China, India, the Netherlands, Spain, the US and Mexico, with approximately 2,000 employees. ‘DSM and Sinochem have been great supporters of our vision to be the global leader in generic pharmaceuticals,’ said Karl Rotthier, who heads DSP. ‘Bain Capital is now the ideal partner to drive DSP into its next stage of global development, given its deep healthcare expertise and operational skills across its worldwide team,’ he said.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to elena.di@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever